Clinical observation of the transition from short-term intensive insulin therapy to IDegLira combined with metformin in Chinese patients with type 2 diabetes mellitus
- P 195-200
The safety and efficacy of transitioning from short-term intensive insulin therapy to a regimen of insulin degludec/liraglutide (IDegLira) combined with metformin in type 2 diabetes mellitus patients is evaluated in the present study. Conducted at Shenzhen Luohu Hospital Group, the study involved 81 patients who switched from continuous subcutaneous insulin infusion to IDegLira and metformin after four days. Results showed significant improvements: insulin doses decreased from 40.28 to 14.79 IU, HbA1c levels fell from 9.94% to 7.67%, and body weight slightly reduced. The transition also enhanced glycemic control, with reduced mean glucose and variation, and increased time in range.
IDegLira metformin short-term intensive insulin therapy type 2 diabetes mellitus